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Enterohemorrhagic Escherichia coli (EHEC) are responsible for major outbreaks of bloody
diarrhea and hemolytic uremic syndrome (HUS) throughout the world. The mortality
associated with EHEC infections stems from the production and release of a potent
Shiga toxin (Stx) by these bacteria. Stx induces cell death in endothelial cells, primarily in
the urinary tract, causing HUS. Stx was first described in Shigella dysenteriae serotype
I by Kiyoshi Shiga and was discovered later in EHEC. Multiple environmental cues
regulate the expression of Stx, including temperature, growth phase, antibiotics, reactive
oxygen species (ROS), and quorum sensing. Currently, there is no effective treatment or
prophylaxis for HUS. Because antibiotics trigger Stx production and their use to treat EHEC
infections is controversial, alternative therapeutic strategies have become the focus of
intense research. One such strategy explores quorum sensing inhibitors as therapeutics.
These inhibitors target quorum sensing regulation of Stx expression without interfering
with bacterial growth, leading to the hypothesis that these inhibitors impose less selective
pressure for bacteria to develop drug resistance. In this review, we discuss factors that
regulate Stx production in EHEC, as well as novel strategies to prevent and/or minimize
the development of HUS in infected subjects.
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SHIGA TOXIN: AN INTRODUCTION
Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a deadly
human pathogen that causes gastrointestinal (GI) infections
worldwide. Annually in the United States, EHEC is responsible
for an estimated 73,000 illnesses, 1800–3600 hospitalizations and
from 61 to 541 deaths (Rangel et al., 2005) (www.cdc.gov). EHEC
is a foodborne pathogen, and outbreaks occur through ingestion
of contaminated food or water including: contaminated ground
beef, steak, salami (Bell et al., 1994; Jay et al., 2004; Greig and
Ravel, 2009), dairy products (raw milk, cheese, butter, cookie
dough) (Jaeger and Acheson, 2000; Neil et al., 2012) and vegeta-
bles (spinach, lettuce, sprouts) (Rangel et al., 2005; Grant et al.,
2008; Wendel et al., 2009; Sodha et al., 2011). A remarkable fea-
ture of EHEC infection is its low infectious dose; it is estimated
that 50–100 colony forming units (CFUs) of EHEC is sufficient to
cause disease in healthy individuals (Tilden et al., 1996).
Although EHEC is a human pathogen, this bacterium resides
as a commensal in the GI tract of cattle (Savageau, 1983; Naylor
et al., 2003). Fecal shedding from cattle represents an important
source of EHEC contamination and transmission (Arthur et al.,
2011). Many studies have focused on the eradication of EHEC
from the GI tract of ruminants to reduce the infection rate of this
enteric pathogen (Rivas et al., 2010; Vilte et al., 2011).
EHEC implements two major virulence strategies: produc-
tion of Shiga toxin (Stx) and formation of attaching and effacing
(AE) lesions on enterocytes (Kaper et al., 2004). EHEC contains
a pathogenicity island termed the locus of enterocyte effacement
(LEE), which is crucial for the development of AE lesions
(McDaniel et al., 1995). The LEE encodes a master regulator for
its own expression, ler (Mellies et al., 1999); a type 3 secretion
(T3S) apparatus (Jarvis et al., 1995), translocator proteins EspA
(Knutton et al., 1998) and EspB (Kenny and Finlay, 1995; Abe
et al., 1997), an adhesin Intimin (Jerse et al., 1990) and its own
receptor, the translocated intimin receptor (Tir) (Kenny et al.,
1997). AE lesions are characterized by extensive actin remodel-
ing of the host cell cytoskeleton, leading to effacement of the
microvilli and formation of a pedestal-like structure beneath the
bacteria (Tzipori et al., 1992; Deng et al., 2001; Campellone et al.,
2004; Garmendia et al., 2004; Vingadassalom et al., 2010). It
should be highlighted that the initial findings of AE lesion for-
mation described in the references above (Jerse et al., 1990, 1995;
Kenny and Finlay, 1995; Abe et al., 1997; Knutton et al., 1998;
Mellies et al., 1999) were discovered in enteropathogenic E. coli
(EPEC), however, the proteins Ler, Intimin, Tir, EspA, and EspB
are conserved between EHEC and EPEC.
EHEC infection leads to a characteristic bloody diarrhea,
which self-resolves in most cases. However, in approximately
5–7% of the cases, the patient develops a complication known
as hemolytic uremic syndrome (HUS) (Karmali, 2004; Noris and
Remuzzi, 2005; Tarr et al., 2005). HUS is the most serious seque-
lae of EHEC infection, and its incidence is higher in children
and the elderly (Brandt et al., 1990; Gould et al., 2009). The
disease is characterized by thrombocytopenia, hemolytic anemia
and acute renal failure. In children infected by EHEC, HUS often
develops soon after the onset of diarrhea (Wong et al., 2000).
HUS is a life-threatening disease, contributing to a 5% mortal-
ity rate. The development of HUS is a direct result of the release
of Stx, a very potent toxin encoded in a bacteriophage in the
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EHEC chromosome (Kaper et al., 2004). Stx also contributes to
the development of hemorrhagic colitis by lysing endothelial cells
from the intestinal mucosa (Tarr et al., 2005).
The current treatment for EHEC infection is supportive, due
to the lack of specific therapies to clear the infection or to prevent
its sequelae (Michael et al., 2009). Several drugs commonly used
in the clinic to treat bacterial infections are not advised for treat-
ment of EHEC-infected patients, such as antibiotics, antimotility
agents, narcotics, and non-steroidal anti-inflammatorymedicines
(Tarr et al., 2005). The increasing number of outbreaks and HUS
cases highlight the urgent need for new treatments.
In this review, we will focus on the mechanism by which
Stx causes the development of HUS and how Stx expression
is regulated within EHEC. We will discuss novel strategies that
are currently being developed to treat EHEC infection and to
ameliorate the severity of HUS.
SHIGA TOXIN AND HUS
The first outbreak in the United States of EHEC O157:H7 was
reported in 1982 and it was linked to the consumption of con-
taminated hamburger meat fromMcDonald’s inMichigan. EHEC
O157:H7 was a rare serotype prior to the 1982 outbreak (Riley
et al., 1983). At present, however, O157:H7 is the major serotype
responsible for outbreaks of hemorrhagic colitis throughout the
world. EHEC O157:H7 encodes for Stx in a bacteriophage in the
EHEC chromosome, and release of Stx by EHEC is the predom-
inant cause of mortality in EHEC infections. A potent cytotoxin,
Stx is produced by the enteric pathogens Shigella dysenteriae
serotype I and a collective group of E. coli strains called Stx-
producing E. coli (STEC). Stx from S. dysenteriae serotype I was
first identified by Kiyoshi Shiga (Fraser et al., 2004). In 1983, it
was first reported that EHEC could also produce Stx (O’Brien
et al., 1983a), providing the link between Stx production and
the development of HUS (Karmali et al., 1983). Initially, Stx was
called Verotoxin due to its cytotoxicity against Vero cells in cul-
ture. Upon the discovery that Verotoxin could be neutralized by
an antitoxin against purified Stx from Shigella, the name Stx came
into use and is the more common name to date (O’Brien et al.,
1983b). Stx and Verotoxin are used interchangeably, but for the
purpose of this review, only Stx and the STEC strain EHEC will
be discussed (Table 1).
Since 1982, EHEC has been recognized as a major enteric
pathogen. An increase in the number of recent outbreaks is
attributed to the emergence of more virulent strains (Kulasekara
et al., 2009). In 1999, the largest reported outbreak to date
occurred in the United States, as a result of a contaminated water
well; 781 people were infected, with 9% hospitalized and 2%
developing HUS (www.cdc.gov). In a 2006 outbreak caused by
Table 1 | Stx family and variants.
Stx type Variants
Stx1 Stx1, Stx1c, Stx1d
Stx2 Stx2(Stx2a), Stx2c, Stx2c2, Stx2d, Stx2dactivatable,
Stx2e, Stx2f
contaminated spinach, 29% of the patients developed HUS, indi-
cating a rise in the incidence of HUS from previous outbreaks that
reported an incidence of 15–20% (Grant et al., 2008). Genomic
analysis of an isolate from the spinach outbreak revealed the pres-
ence of two stx-encoding genes, stx2 and stx2c (Neupane et al.,
2011).
The highest number of HUS cases reported to date occurred in
a 2011 German outbreak, suggesting that STEC has increased its
virulence over time. Genomic analyses of this isolate determined
that the infective strain was actually an enteroaggregative E.coli
(EAEC) that had acquired a lambdoid-like phage encoding stx2
(Rasko et al., 2011). EAEC forms a biofilm in the intestine, a trait
that makes treatment challenging (Sheikh et al., 2001). The com-
bined ability to form a biofilmwith the production of Stx resulted
in a highly virulent STEC strain that caused 34 deaths and 908
HUS cases in 2011. The causative agent of the 2011 German out-
break was identified as a non-LEE Stx-producing E.coli serotype
O104:H4, EAEC (Buchholz et al., 2011).
MECHANISMOF ACTION OF SHIGA TOXIN
Stx inhibits protein synthesis and induces apoptosis. Stx is an AB5
toxin, constituted by a catalytic subunit A bound non-covalently
to a pentamer of B subunits (Stein et al., 1992; Fraser et al.,
1994). The A subunit has N-glycosidase activity that cleaves an
adenosine residue from 28S ribosomal RNA of the 60S ribosomal
subunit (Endo et al., 1988). As a result, it inhibits protein syn-
thesis, causing cell death by apoptosis. The five B subunits form
a structure that binds the globotriaosylceramide (Gb3) receptor
on the surface of eukaryotic cells (Jacewicz et al., 1986; Lindberg
et al., 1987). Gb3 is expressed by Paneth cells in the intestinal
mucosa and by kidney epithelial cells [reviewed in (Tarr et al.,
2005)] (Figure 1). Stx enters systemic circulation through absorp-
tion by the epithelium (Acheson et al., 1996), enabling its access
to the kidneys. The damage of the GI epithelium caused by EHEC
likely aids in Stx systemic absorption (Mukherjee et al., 2002).
Upon receptor binding, Stx is endocytosed by the eukaryotic cell
(Romer et al., 2007), bypasses the late endocytic pathway and
undergo retrograde transport from the trans-Golgi network to
the endoplasmic reticulum (ER) where it encounters its target
(Sandvig et al., 1992; Mallard et al., 1998). These processes have
been reviewed in detail elsewhere (Johannes and Romer, 2010).
The Stx family has two main groups, Stx1 and Stx2. The
Stx1 family consists of the variants Stx1, Stx1c, and Stx1d. The
Stx2 family is composed of the variants Stx2c, Stx2c2, Stx2d,
Stx2dactivatable, Stx2e, and Stx2f (Muthing et al., 2009). The Stx2
variants differ in their biological activity, immunological reactiv-
ity, and the receptor to which they bind. These binding properties
allow the Stx variants to target different cell types (Fraser et al.,
2004).
Although Stx1 and Stx2 share enzymatic activity and structural
features, they are immunogically distinct. Stx1 is nearly identi-
cal to Stx from Shigella, with a difference in only a single amino
acid in the catalytic A subunit. Conversely, Stx2 shares only 55%
amino acid sequence similarity to Stx1 (Fraser et al., 2004). Stx2
is more potent than Stx1 in humans (Nishikawa et al., 2000),
and it is commonly associated with hemorrhagic colitis and HUS
(Nataro and Kaper, 1998; Boerlin et al., 1999). The two subgroups
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FIGURE 1 | Mechanism of action of Shiga toxin (Stx). Stx is constituted by
a pentamer of B subunits bound to a catalytic A subunit. The B subunits bind
to globotriaosylceramide (Gb3) expressed by some eukaryotic cells (1) Stx is
internalized by endocytosis (2) Subsequently, Stx undergoes retrograde
transport to the trans-Golgi network (TGN) (3) and then to the endoplasmic
reticulum (ER) (4) In the ER, Stx encounters its target, the ribosome,
inactivating it (4) As a consquence, Stx inhibits protein synthesis, causing cell
death by apoptosis.
of Stx can be found in different combinations in EHEC isolates.
Epidemiological studies suggest that EHEC strains encoding Stx2
are more likely to cause severe disease than isolates that harbor
only Stx1 or a combination of Stx1 and Stx2 (Ritchie et al., 2003).
There are conflicting reports concerning the effect of Stx on the
generation of an inflammatory response. One study found that
Stx and flagellin act in concert to activate expression of IL-8 and
promote inflammation (Jandhyala et al., 2010). Matussek and col-
leagues reported an increased expression of IL-8 in the presence
of Stx1 or Stx2 (Matussek et al., 2003). In contrast, Bellmeyer
et al. (Bellmeyer et al., 2009) reported that while Stx activates
IL-8, EHEC produces other factors that lead to suppression of the
inflammatory response in intestinal epithelial cells.
ANIMAL MODELS FOR EHEC INFECTION AND Stx
Many animal models to study the pathogenesis of EHEC infec-
tion in vivo have been developed. Some of these models are more
suitable to study colonization, while others are more informative
to evaluate the effects of Stx. Nonetheless, no animal model cur-
rently available is able to mimic all aspects of EHEC-mediated
disease, including infectious dose or development of hemorrhagic
colitis and HUS (Mohawk and O’Brien, 2011). The animal mod-
els include: mice, rats, infant rabbits (Pai et al., 1986; Ritchie et al.,
2003), gnotobiotic piglets, gnotobiotic calves, and primates.
A mouse model is usually the choice for in vivo studies, due
to lower cost, easier maintenance, availability of reagents and
knockout strains. The first mouse model for EHEC infection was
developed by Wadolkowski and colleagues (Wadolkowski et al.,
1990), and was based on the model developed by Myhal (Myhal
et al., 1982), who studied colonization by non-pathogenic E.coli
strains. In this model, the animals receive antibiotics in their
drinking water prior to EHEC infection to reduce the microbial
flora and diminish competition with EHEC. CD-1 mice receive
antibiotics before an overnight fast and are subsequently infected
with 1010 CFU of EHEC. Under these conditions, EHEC sta-
bly colonizes the small and large intestines for about a month.
However, the mice do not develop diarrhea or any other hallmark
GI symptoms of EHEC infection.
Because most of the mouse models developed to date require
manipulation such as antibiotic treatment (Wadolkowski et al.,
1990), dietary restrictions, or mitomycin C administration to
improve Stx expression, Mohawk and colleagues developed a
model that maintains an intact commensal flora (ICF) (Mohawk
et al., 2010b). They infected BALB/c mice with different inocu-
lums and assessed bacterial colonization by CFU recovery from
intestinal segments and stool. A high infectious dose (109 CFU)
resulted in the highest colonization rate and bacterial recov-
ery compared to lower ones (105, 106, 107, and 108 CFU). The
highest levels of Stx are detected in the large intestinal con-
tents. Histopathology analysis of kidney sections shows mild
kidney damage, suggesting Stx systemic effects. This study sug-
gests that by using a high infectious dose, mice can be colonized
by EHEC without alteration to their commensal gut microbiota.
This model represents an advance in the use of mice to study
EHEC colonization and persistence. However, a disadvantage of
this particular model is the absence of hemolytic anemia and
thrombocytopenia, making the ICFmice more attractive for colo-
nization studies than evaluation of systemic effects resulting from
EHEC infection. The reports using mice as a model for EHEC
infection have to be interpreted with caution.Mice do not develop
diarrhea, and AE lesions are not observed. Also, it is of note that
the bacterial inoculum used in these experiments is many orders
of magnitude higher than the estimated infectious dose of EHEC
(50–100 CFU).
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Gnotobiotic piglets are highly susceptible to EHEC infection.
The gnotobiotic piglet model was developed by Tzipori in 1986
(Tzipori et al., 1986), and this model has been a useful tool to
study Stx-mediated pathogenesis and the systemic effects of Stx.
(Mukherjee et al., 2002). Upon infection by EHEC, these animals
develop watery diarrhea, colitis and inflammation, and EHEC
forms the characteristic AE lesions in their intestinal epithelium
(Tzipori et al., 1986). Although the gnotobiotic piglets do not
develop HUS, they demonstrate several signs of systemic disease
including convulsions, tremor, ataxia, and brain hemorrhage.
Formation of thrombotic microangiopathy, which causes acute
kidney failure, was observed when gnotobiotic piglets were orally
infected by 108–1010 CFU of EHEC (Gunzer et al., 2002). The
gnotobiotic piglet model best represents the systemic effects of
EHEC infection seen in humans, and it is an excellent model to
study EHEC pathogenesis in vivo. However, a drawback of using
this animal model is the requirement of a complex animal facility
to perform the experiments.
The infant rabbit model is also used to study EHEC patho-
genesis in vivo. Developed by Pai and colleagues in 1986 (Pai
et al., 1986), 3-day-old infant rabbits are inoculated intragastri-
cally with 108 CFU of EHEC. The rabbits develop diarrhea and
colonic inflammation, and a portion succumb to death. In 2003,
Ritchie and colleagues investigated the contribution of individual
virulence factors on the development of disease by using EHEC
isogenic mutants to infect infant rabbits (Ritchie et al., 2003).
The infant rabbit model allowed the evaluation of Stx2, as well
as the receptor and ligand crucial for AE lesion formation—Tir
and Intimin, respectively, in the pathogenesis of EHEC infec-
tion, by inoculating 3-day-old New Zealand white rabbits with
5 × 108 CFU/90 g body weight of wild type EHEC or the EHEC
isogenic mutants stx2, eae or tir. When the infant rabbits are
infected with wild-type EHEC, the animals develop diarrhea and
intestinal inflammation but not HUS. The absence of the Stx
receptor Gb3 in the rabbit kidneys likely accounts for the lack of
HUS in these animals (Zoja et al., 1992). Similarly to gnotobi-
otic piglets, infant rabbits infected with EHEC develop AE lesions
on their intestinal epithelium (Ritchie et al., 2003). However, in
the absence of Tir or Intimin, EHEC cannot colonize the intes-
tine or cause disease, indicating the important role that AE lesion
formation plays in pathogenesis. Stx2 promotes an inflammatory
response at the intestinal mucosa but does not contribute to col-
onization, as shown by infection of rabbits with a stx2 mutant of
EHEC or administration of purified Stx2. The infant rabbitmodel
is useful to study the intestinal pathogenesis of EHEC infection,
and it is advantageous to the gnotobiotic piglet model in its cost
effectiveness.
The development of an animal model that would mimic the
whole spectrum of EHEC disease would be invaluable to study
preventive strategies and to test new therapies. While the infant
rabbit model allows monitoring of hemorrhagic colitis and AE
lesions without the requirement of complex animal facilities, the
gnotobiotic piglet represents the best animal model available for
investigation of systemic effects of EHEC infection. An animal
model that mimics the human infectious dose (50–100 CFU) is
not available yet. The remarkably low infectious dose is an impor-
tant aspect of EHEC infection. Understanding the initial events
that lead to colonization of the human intestine, especially the
role of host factors, will provide insight into how EHEC can
rapidly proliferate and establish disease in humans.
REGULATION OF Stx EXPRESSION
PHAGE CYCLE AND SOS RESPONSE
In EHEC O157:H7, Stx is encoded by two toxin-converting bac-
teriophages in the chromosome, 933W and 933J (O’Brien et al.,
1984). The genes encoding stx are located in intact or partial
genomes of prophages from the lambda family, which are inte-
grated into the bacterial chromosome (Johansen et al., 2001).
Activation of the phage lytic cycle leads to Stx production (Neely
and Friedman, 1998), which is then released upon bacterial cell
lysis.
The genes encoding Stx1 and Stx2 are located within the late
phage genes, where expression of stxAB is under control of the
phage cycle. Stx2 is only produced when the phage enters its lytic
cycle (Tyler et al., 2004), while Stx1 is regulated by phage cycle and
an iron-regulated promoter (Calderwood and Mekalanos, 1987;
Wagner et al., 2002). The lambda phage remains quiescent due
to the binding of the cI repressor to the right (OR) and left (OL)
operator sites, in turn inhibiting the activity of the phage early
promoters PR and PL (Waldor and Friedman, 2005). To enter
its lytic cycle, the bacteriophage encoding stxAB takes advan-
tage of the bacterial cell SOS response. Upon triggering of the
SOS response, RecA is produced and activated (Muhldorfer et al.,
1996). The activated form of RecA promotes cleavage of the cI
repressor, de-repressing PR. Absence of cI leads to the expression
of the anti-terminators N and Q. The protein Q then binds to PR′
to activate the late phage genes, including stxAB. Bacteria undergo
lysis and release Stx into the environment (Figure 2). A study of
the promoters and regulatory regions of the 933W phage provides
evidence that cI removal is required for Stx production by the bac-
terial cell. A 933W derivative encoding a non-cleavable repressor
cannot produce Stx (Tyler et al., 2004).
REGULATION BY ANTIBIOTICS
The use of antibiotics for the treatment of STEC infection is con-
troversial due to its effect on induction of the phage lytic cycle
(Zhang et al., 2000). Many studies have shown that antibiotics
such as quinolones and mitomycin C increase the production of
Stx (Zhang et al., 2000; McGannon et al., 2010). Specifically, mit-
omycin C is commonly used in research for prophage induction
for its ability to interfere with DNA replication, triggering an SOS
response (Los et al., 2010).
In a clinical study, Wong et al. followed the course of dis-
ease in 71 children who had diarrhea caused by EHEC O157:H7.
Treatment of infected children with the antibiotic trimethoprim-
sulfamethoxazole (SXT) led to a relative risk of 17.7% of devel-
oping HUS, while treatment based on beta-lactamic antibiotics
contributed to a 13.4% relative risk (Wong et al., 2000). A
recent study conducted by McGannon and colleagues supports
the finding that the use of SXT and quinolones worsen a patient’s
outcome during EHEC infection (McGannon et al., 2010). These
authors investigated the influence of antibiotics on Stx produc-
tion: azithromicin (AZM), doxycycline (DOX), phosphomycin
(FOS) and gentamycin (GEN) decreased Stx production, while
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FIGURE 2 | Regulation of Shiga toxin expression by the phage
cycle. The cI repressor bound to operator sites OL and OR inhibitis
transcription from the promoters PL and PR . The presence of terminator
downtream of PR′ inhibits transcription of stxAB and the phage remains
quiescent. When SOS response is triggered, RecA cleaves cI,
relieving PR repression and expression of antiterminators N and Q.
Antiterminator Q binds PR′ leading to transcription of stxAB genes
with the late phage genes.
ampicillin (AMP), SXT and ciprofloxacin (CIP) increased Stx
production. The antibiotics ceftriaxone (CRO) and rifampin
(RIF) did not affect Stx production. Their results confirm that
antibiotics that target DNA synthesis trigger Stx production, and
suggest that antibiotics that target protein synthesis and cell wall
synthesis inhibit Stx production.
Quinolones are a class of antibiotics known to induce produc-
tion of Stx, due to the activation of the SOS response in EHEC.
A study conducted by Zhang et al. (Zhang et al., 2000) showed
that administration of CIP and FOS caused a reduction in the
bacterial burden of EHEC in the feces. However, treatment of
infected mice with CIP resulted in increased levels of Stx in feces,
as well as increased mortality. Conversely, treatment with FOS
did not increase Stx production (Zhang et al., 2000). FOS is an
inhibitor of cell wall synthesis, and it does not induce bacterio-
phages. This study contributes to a better understanding on the
effects of different classes of antibiotics for treatment of EHEC
infections.
Further in vivo investigations would help to determine whether
Stx-inhibitory antibiotics are potentially beneficial to treat EHEC-
infected individuals, yet it is still premature to endorse antibiotic
treatment for EHEC infection.
REGULATION BY OTHERMECHANISMS
Nitric oxide
Nitric oxide (NO) inhibits the synthesis of Stx by EHEC (Vareille
et al., 2007). Vareille and colleagues reported that stx2 expres-
sion during stationary growth phase could be diminished by
administration of the NO donor NOR4. The inhibitory effect of
NO was evident when EHEC was grown in the presence of mit-
omycin C, a known inducer of Stx production. In addition, the
use of the NO scavenger compound cPTIO could restore stx2
expression and Stx2 production in NO-treated EHEC cultures
(Vareille et al., 2007). Interestingly, the inhibitory effect of NO
was also seen at the phage particle levels. NOR4 reduced the
number of 933W phage released after SOS-induction by mito-
mycin C. Treatment with NO dramatically reduces the expression
of recA, therefore, the inhibitory effect of NO over Stx is due to
interference with the bacterial SOS response.
Hydrogen peroxide (H2O2)
DNA-damaging agents such as mitomycin C and UV irradiation
trigger Stx-expressing phages, yet these signals are unlikely to be
encountered in vivo. Many investigators have focused on identi-
fying agents present in the human intestine that might contribute
to Stx production leading to HUS. Neutrophils and other cells
produce NO and H2O2, that are known to damage DNA and
potentially trigger an SOS response in bacteria (Imlay and Linn,
1987; Lobysheva et al., 1999).
Wagner and colleagues (Wagner et al., 2001) investigated the
possible participation of H2O2 and neutrophils in Stx produc-
tion and phage induction in EHEC. Exposure of EHEC to H2O2
in vitro resulted in increased Stx production in a dose-dependent
manner, as well as an increase in phage titers. Incubation of
EHEC with human neutrophils increased Stx production, indi-
cating that neutrophil-derived products might induce an SOS
response leading to Stx release (Wagner et al., 2001). A study
by Los and colleagues (Los et al., 2010) corroborated findings
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that H2O2 increases Stx production. An investigation of possible
prophage triggers found that although high osmolarity did not
affect prophage induction, the addition of millimolar concentra-
tions of H2O2 resulted in phage production comparable to the
amounts generated by addition of the antibiotic norphloxacin.
Oxidative stress conditions during host colonization, such as
reactive oxygen species (ROS) produced by commensal bacteria,
might enhance Stx production in vivo, thereby contributing to
EHEC pathogenesis.
Iron
The concentration of iron affects the production of Stx1; low-
iron conditions lead to increased amounts of Stx1 (O’Brien et al.,
1982). Regulation of stx1AB by iron has been demonstrated
(Weinstein et al., 1988), but iron seems to have no impact on
the expression of stx2AB genes (Muhldorfer et al., 1996). High
levels of iron repress the activity of the stx1AB iron-dependent
promoter, thereby reducing Stx1 production. Specifically, repres-
sion of stx1AB by iron is mediated by Fur (Calderwood and
Mekalanos, 1987).
Environmental conditions
The conditions that govern the switch between lysogenic and
lytic phage growth affect Stx production. During the lytic stage,
a phage produces and releases Stx. The study of environmental
cues and regulatory pathways that lead to expression of stx genes
is fundamental to the development of novel strategies to prevent
Stx production or counteract the effects of the toxin in order to
avoid HUS.
Muhldorfer and colleagues (Muhldorfer et al., 1996) investi-
gated the effects of different environmental conditions on the
expression and production of Stx2. By using a translational
reporter fusion for Stx2 synthesis, they demonstrated that the
global regulatory protein H-NS regulates the expression of stx2
by modulating its promoter activity and the synthesis of Stx2 by
modulation of the phage induction. Growth temperature has a
moderate effect on Stx production and has been linked to H-NS
regulation. The synthesis of Stx2 increased at 30◦C but decreased
at 42◦C, in the hns-mutant strain. However, conditions such as
pH, osmolarity, oxygen tension, acetates, iron levels, or carbon
sources did not affect stx2 expression.
Stationary phase
Earlier studies suggest that stationary growth increases production
of Stx. Konowalchuk et al. reported maximal cytotoxic activity
when the bacterial cultures were shaken for 24 h (Konowalchuk
et al., 1978), a condition where the bacterial cells enter stationary
phase, and stxAB are induced (Bergholz et al., 2007) (Table 2).
REGULATION BY STRESS
Mammalian cells communicate with each other via hormones.
Bacterial cells, although unicellular, can also communicate with
each other through the production and detection of small
molecules known as autoinducers (AIs) (Nealson et al., 1970).
AIs are hormone-like compounds produced by commensal and
pathogenic bacteria, and they are involved in the coordination
of behavior and adaptive responses (Sperandio et al., 2003). This
Table 2 | Regulation of Stx expression.
Stx type Regulation References
Stx1 Phage cycle Neely and Friedman, 1998
Iron O’Brien et al., 1982; Calderwood
and Mekalanos, 1987
Stx2 Phage cycle Muhldorfer et al., 1996
Antibiotics Wong et al., 2000; Zhang et al.,
2000; McGannon et al., 2010
Stationary phase Konowalchuk et al., 1978;
Bergholz et al., 2007
Temperature Muhldorfer et al., 1996
Nitric Oxide Vareille et al., 2007
Hydrogen Peroxide Wagner et al., 2001; Los et al.,
2010
Stress Reading et al., 2007;
Hughes et al., 2009
Hfq Kendall et al., 2011
communication is known as quorum sensing, and it coordinates
multiple phenotypes in bacteria (Fuqua et al., 1994).
Pathogenic bacteria use cell-to-cell communication to regu-
late the production of virulence factors. EHEC can also hijack
the mammalian stress response hormones epinephrine (epi)
and norepinephrine (NE) to regulate expression of its major
pathogenic traits: AE lesion formation, flagellar motility, and Stx
production (Sperandio et al., 2001). The communication between
bacteria and its host is called inter-kingdom signaling (Pacheco
and Sperandio, 2009).
Many quorum sensing systems are composed of two compo-
nent systems (TCS) that incorporate a sensor histidine kinase
(HK) and a response regulator (RR) to regulate signal transduc-
tion, including quorum sensing-mediated virulence regulation in
EHEC (Clarke et al., 2006; Reading et al., 2007; Hughes et al.,
2009). Upon sensing its signal, the HK autophosphorylates at a
conserved histidine residue and subsequently transfers its phos-
phate to a conserved aspartate residue in the RR. Then, the RR
undergoes conformational changes that allows it to bind DNA,
promoting changes in gene expression (Stock et al., 2000).
EHEC encodes for the QseBC TCS (Sperandio et al., 2002),
that senses bacterial-derived AI-3 and host-produced epi/NE
(Hughes et al., 2009). The QseC sensor kinase is the first adren-
ergic sensor described in bacteria (Clarke et al., 2006), and it is
the only sensor of AI-3 in EHEC. Hughes et al. (Hughes et al.,
2009) reported that stx2 expression is diminished in the qseC
mutant. Transcriptional analysis showed that QseC regulates stx2
expression through activation of recA. These findings demon-
strate that the bacterial adrenergic receptor QseC participates in
the generation of the SOS response in bacteria (Hughes et al.,
2009). In the same study, it was demonstrated that the TCSQseEF
(Reading et al., 2007) also regulates expression of stx2. QseEF
expression is activated by QseBC, and QseC phosphorylates the
non-cognate RR QseF. It was shown that QseC-mediated acti-
vation of stx2 expression occurs via QseF (Hughes et al., 2009).
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The QseC sensor is present in 25 species of Gram-negative bacte-
ria (Rasko et al., 2008). Taken together, these results demonstrate
that bacterial cell-to-cell signaling plays a major role in the reg-
ulation of stx expression and may represent a suitable target for
novel anti-virulence therapies for EHEC.
The importance of global regulators in the modulation of stx2
gene expression is exemplified by a recent study performed by
Kendall et al. (Kendall et al., 2011). It was demonstrated that
the RNA chaperone Hfq regulates the expression of stx2. Hfq is
an RNA chaperone that mediates post-transcriptional regulation
through small RNAs (sRNA) (Vogel and Luisi, 2011). Deletion
of hfq in EHEC 86–24 and EDL933 strains results in increased
expression of stx2AB genes and increased production of Stx2
(Kendall et al., 2011). These data demonstrate that Hfq decreases
stx2 expression and consequently plays an important role in the
development of HUS upon EHEC infection.
NOVEL THERAPIES
The increasing knowledge on regulation of stx expression and
its mechanism of action has contributed to the development of
new strategies to counteract its effects and to prevent disease.
To date, three major strategies seem promising: quorum sensing
inhibitors to interfere with virulence and Stx production; vaccines
and immunotherapies to prevent and treat infection by STEC;
and toxin inhibitors to avoid receptor binding. We present and
discuss these strategies in this section.
INHIBITION OF QUORUM SENSING
Bacterial cells are able to sense their surroundings and regulate
gene expression in an adaptive manner (Rasko and Sperandio,
2010). Environmental cues are used to fine-tune gene regula-
tion and avoid energy waste. Pathogenic bacteria including EHEC
can sense chemical signals present in the host environment to
trigger the expression of virulence genes and ultimately promote
colonization of the host (Hughes et al., 2009). Therefore, under-
standing the interaction between EHEC and its host is imperative
to fight bacterial infection. The identification of mechanisms
involved in the regulation of virulence gene expression allows the
development of strategies to prevent that triggering event, dimin-
ishing the ability of the bacteria to colonize its host. By interfering
with the sensing mechanisms harbored specifically by pathogenic
bacteria, bacterial colonization of the host can be minimized or
eliminated.
Many bacteria share the ability to sense epi/NE via the adren-
ergic sensor QseC (Sperandio et al., 2003). It has been reported
that qseC knockouts in EHEC (Clarke et al., 2006), Salmonella
typhimurium (Bearson and Bearson, 2008; Moreira et al., 2010)
and Francisella tularensis (Weiss et al., 2007) are attenuated in
animal models. Due to the important role of QseC in virulence
regulation in these pathogens, Rasko et al. (Rasko et al., 2008)
conducted a high-throughput screen (HTS) of a chemical library
of small molecules in an attempt to identify an inhibitor of viru-
lence regulation mediated by QseC. The HTS led to the discovery
of the small molecule LED209 that targets QseC. LED209 pre-
sented little toxicity against bacterial and human cell lines and
did not inhibit bacterial growth. In the same report, it was shown
that LED209 counteracted the effects of epi on the expression of
FIGURE 3 | Inhibition of signal transduction by LED209. LED209
prevents autophosphorylation of the adrenergic sensor QseC, which is
required to activate the expression of genes involved in colonization of the
intestinal epitheliu.
the LEE and stx2. Most importantly, LED209 did not trigger an
SOS response in EHEC; in fact, the drug decreased stx2 expres-
sion. These results demonstrated that LED209 inhibits QseC-
mediated virulence gene expression (Figure 3). The inhibitory
effect of LED209 was also seen at the level of protein activ-
ity, since QseC autophosphorylation in the presence of epi was
inhibited with the addition of LED209. The activity of LED209
was also tested against the QseC-encoding bacterial pathogens
Salmonella typhimurium and Francisella tularensis, and it was
shown to be effective in vivo against these pathogens (Rasko et al.,
2008).
Since quorum sensing inhibitors such as LED209 do not affect
bacterial growth, it is thought that less selective pressure for resis-
tance against the drug will occur. Also, quorum sensing inhibitors
have the advantage of presenting selective toxicity, since the tar-
geted sensory mechanisms are usually absent from eukaryotic
cells. However, strategies involving reduction of virulence are not
devoid of disadvantages. One of the drawbacks is the narrow
spectrum of activity. The signaling systems might be pathogen-
specific and not be suitable for use in the treatment of a diverse
range of bacterial infections, in contrast to classic antibiotics. In
addition, the presence of homologues of the target signal trans-
duction systems in members of the microbiota might have an
undesirable impact on the homeostasis of the GI tract. Lastly, the
use of quorum sensing inhibitors has not been tested in clini-
cal trials so no information exists about possible side effects in
humans. Nonetheless, the multiple advantages of quorum sens-
ing inhibitors make them attractive for treatment of bacterial
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infections. It appears that the future of treatment of EHEC-
mediated disease might rely on the ability to design chemicals that
directly target the bacterial receptors regulating Stx expression
and production.
PYOCINS
A study published by Ritchie et al. (Ritchie et al., 2011) explored
the use of R-type pyocins to combat EHEC infection in vivo.
R-type pyocins are bacteriocins produced by some Pseudomonas
aeruginosa strains. These proteins form structures similar to tails
of the bacteriophages from the Myoviridae family, which insert
themselves into the bacterial cell envelope after contact with
a specific cell receptor. R-type pyocins bind surface structures
on the target cell and form pores at the cell membrane, caus-
ing membrane depolarization and cell death. The bactericidal
activity of R-type pyocins toward EHEC was first investigated
by Scholl et al. (Scholl et al., 2009), who constructed an EHEC
O157-specific pyocin, AvR2-V10. These authors reported that
AvR2-V10 could specifically degrade O157-LPS without induc-
ing Stx production. Ritchie et al. (Ritchie et al., 2011) constructed
a variant of AvR2-V10, named AvR2-V10.3, and tested it for
antibacterial activity against EHEC in vivo using the infant rabbit
model. Rabbits treated with AvR2-V10.3 after EHEC infection did
not develop diarrhea and presented less intestinal inflammation.
Also, administration of AvR2-V10.3 reduced intestinal coloniza-
tion and bacterial shedding in stool. The pyocin treatment was
also beneficial even when administrated after the onset of diar-
rhea. These studies suggest that R-type pyocins can be effective to
prevent or treat symptoms caused by EHEC infection.
VACCINES AND IMMUNOTHERAPY
Other strategies under investigation for both the prevention and
resolution of EHEC infection include vaccines, Stx receptor mim-
ics and antibodies against Stx. Many immunization studies have
focused on raising antibodies against purified subunits of the Stx.
A strategy to reduce HUS development is the prevention of
Stx exposure. Although considered a conservative approach in
the field of infectious diseases, immunization of children against
EHEC could prevent the occurrence of disease. Immunization
represents a method to prevent HUS, especially in children, who
succumb to acute kidney failure resulting from EHEC infection
at a higher rate than adults. Many studies have focused on the
development of a vaccine to prevent EHEC infection, while some
studies have demonstrated the protective effect of a Stx vaccine in
mouse or piglet models of infection. However, a vaccine against
EHEC is still not commercially available.
Zhang et al. (Zhang et al., 2011) investigated if immunization
with a combined subunit vaccine containing StxB and Tir frag-
ments protected against EHEC infection. The authors constructed
a multivalent protein constituted of Stx2B-Tir-Stx1B-Zot, where
Zot is an antigen delivery tool that binds a receptor in the intesti-
nal epithelium affecting mucosal permeability. Mice immunized
intranasally with the multivalent protein had reduced coloniza-
tion and reduced amounts of EHEC detected in their stool. Their
results suggest that a multi-antigen vaccine that targets EHEC can
reduce colonization in vivo. However, Stx levels or systemic effects
of Stx were not assessed in this study.
Passive immunotherapy using antibodies against Stx for EHEC
infection has been explored. Many antibodies have been devel-
oped, in an attempt to prevent the devastating pathogenesis of
Stx. The idea behind the use of anti-Stx antibodies to prevent
HUS relies on the time course of EHEC infection. After the
onset of diarrhea, there is a window of time before the develop-
ment of HUS when the administration of passive immunization
might help to prevent the evolution of the disease. Mukherjee
and colleagues (Mukherjee et al., 2002) developed a humanized
monoclonal antibody (HuMAb) against Stx2. In this study, it
was observed that the HuMAbs presented neutralization activity
of 90% and contributed to mice survival in the presence of Stx
injected intravenously.
Mohawk and colleagues (Mohawk et al., 2010a) investigated
the ability of Stx-neutralizing antibodies to affect colonization
by EHEC 86–24. This strain produces only Stx2. BALB/c mice
harboring an ICF were first inoculated with polyclonal rabbit
anti-Stx2 serum and then challenged with EHEC. The admin-
istration of serum had no impact on initial colonization, but it
reduced the CFU detected after 3–5 days post-infection. The anti-
Stx2 serum reduced mortality of mice and reduced weight loss
at later stages in infection (Mohawk et al., 2010a). Vaccination
of infected mice with a Stx2 toxoid resulted in decreased CFU
detected in their feces, suggesting that active immunization leads
to generation of Stx2-neutralizing antibodies in the intestine
(Mohawk et al., 2010a). Although the results were positive, they
have to be interpreted with caution. EHEC infection of mice does
not mimic the human infection in many aspects. EHEC does
not form AE lesions on mouse intestinal epithelial cells, which
is a hallmark of the infection by this pathogen, nor do mice
develop HUS.
INHIBITORS OF TOXIN RECEPTORS
Stx binds to the Gb3 receptor in endothelial cells (Lingwood
et al., 1987), causing intense vascular damage and organ failure.
Therefore, prevention of Stx binding to its receptor is a potential
strategy to reduce Stx-mediated disease.
Many ligands that mimic the Stx receptor Gb3 have been
designed and have shown modest effect of neutralizing toxin
in vitro and in vivo (Kitov et al., 2000; Nishikawa et al., 2000).
However, clinical trials using such compounds have not been
effective (Trachtman et al., 2003). It is possible that the Stx-
neutralizing molecules predominately target the less toxic Stx1
instead of the very potent Stx2 (Kulkarni et al., 2010). Therefore,
new design strategies need account for the subtle variations
between the two Stx forms.
Nishikawa and colleagues explored the neutralization of cir-
culating Stx as a strategy to prevent HUS. Based on the interac-
tion of the toxin with the trisaccharide moieties of its receptor
Gb3, this group designed a series of carbosilane dendrimers car-
rying trisaccharide moieties at their termini that they termed
SUPER TWIG. The rationale was that the compound would
bind Stx in the blood, preventing its access to its receptor
at the host cell. SUPER TWIG binds Stx with high affinity
(Kd = 1.1 × 106− M) and inhibits incorporation of the toxin
in vitro. Mice treated with SUPER TWIG were protected from
EHEC infection upon challenge with a fatal dose. This group
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has optimized the SUPER TWIG structure and determined
the binding site on Stx (Nishikawa et al., 2005), but more
investigations on the mechanism of action are necessary
before SUPER TWIG can be used as a therapeutic for STEC
infections.
An effort to develop Stx2-specific ligands led to the identifi-
cation of a novel ligand using an ELISA-based approach (Kale
et al., 2008), and it served as the basis for the development of
nanoparticles by the same research group (Kulkarni et al., 2010).
Nanotechnology is a novel approach for the development of tar-
geted drug delivery systems to treat several diseases including
cancer and infectious diseases. Kulkarni et al. (Kale et al., 2008)
developed glycan-encapsulated gold nanoparticles (GNP) to dis-
play ligands for Stx. These nanoparticles represent an efficient
material for drug delivery, since it allows multivalent display of
glycans in a similar way to the glycocalyx exposed at the cell
surface. Analogs of the glycan Pk trisaccharide, which binds pref-
erentially to Stx, were developed and used to coat GNP. Toxicity
assays using Vero cells showed that the GNPs successfully neu-
tralized Stx1 and Stx2, but not Stx2 variants Stx2c or Stx2d. Also,
GNPs were not toxic toward Vero cells, based on a protein inhi-
bition assay. These results indicated the therapeutic potential of
ligand-coated nanoparticles, however, further studies on receptor
specificity are needed to address the target of emerging variants
of Stx.
A randomized clinical trial conducted by Trachtman et al.
(Trachtman et al., 2003) assessed the effectiveness of a Stx
inhibitor on the severity of HUS when administered in chil-
dren presenting HUS associated with EHEC infection. One hun-
dred and forty-five children were involved in the trial, and 100
of then received a daily dose of SYNSORB Pk, a drug devel-
oped by SYNSORB Biotech (Alberta, Canada), for seven days.
SYNSORB Pk is constituted by silicone dioxide containing the
trisaccharide moiety of Gb3 that mediates the Stx binding to the
receptor. The rationale was that the drug would compete with
the host cell receptor for Stx binding, preventing the interaction
between Stx andGb3, and consequently reducing the risk of HUS.
Unfortunately, the drug did not reduce the severity of the disease.
Possible explanations for the failure of this trial include that a low
percentage of patients had detectable levels of free Stx in their
stool or that EHEC attachment to the intestinal epithelium could
affect drug access to Stx. Although the results were not positive,
this study represents a major step toward determining a treatment
of HUS.
Inhibitors of the Stx receptor Gb3 are also a target for HUS pre-
vention. C-9 is a specific inhibitor of glucosylceramide (GL1) syn-
thase (Zhao et al., 2007). Silberstein and colleagues (Silberstein
et al., 2011) reported that C-9 was able to downregulate Gb3
expression and prevent Stx2 effects in a tissue culture model using
human kidney cells. Further studies using a ratmodel showed that
oral administration of C-9 for a period of six days protected ani-
mals from the effects of Stx2. It was observed that prophylactic
and post-infection treatment with C-9 reduced the expression of
Gb3 and diminished mortality in infected rats by 50%. Also, C-9
reduced renal tubular necrosis and goblet cell damage as well as
prevented the onset of watery diarrhea in rats injected with Stx2.
Gb3 inhibitors may represent a potential novel therapy to prevent
Stx-mediated disease. Although C-9 counteracted many symp-
toms of Stx-mediated disease, more studies are needed to assess
the possible side effects of downregulation of Gb3 in eukaryotic
cells.
CONCLUSIONS
The increasing incidence of HUS caused by Stx raises the
urgent need for alternative therapies for EHEC infection. Novel
anti-virulence strategies include quorum sensing inhibitors, Stx-
receptor analogs and pyocins. These therapies employ different
mechanisms of action from classic antibiotics, and they are
thought to cause less selective pressure for drug resistance than
classic antibiotics. Although several alternative anti-Stx strategies
have been described in the literature, only one drug reached a
phase 1 clinical trial. Therefore, translational research is neces-
sary to bring new drugs discovered in basic science studies to the
clinic.
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